Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577574 | 0.92 | GAA (0.44) | SIGMAR1GAAKDM4ELMNAUBE2M | |
| SCHEMBL5577823 | 0.91 | HRH3 (0.47) | SIGMAR1GAAKDM4ELMNAKCNH2 | |
| SCHEMBL5577834 | 0.91 | GAA (0.52) | SIGMAR1GAAKDM4ELMNAUBE2M | |
| SCHEMBL5577764 | 0.90 | MEN1 (0.50) | SIGMAR1GAAKDM4ELMNAALDH1A1 | |
| SCHEMBL5577271 | 0.89 | MEN1 (0.45) | SIGMAR1GAAKDM4ELMNACACNA1G | |
| SCHEMBL5577885 | 0.89 | SIGMAR1 (0.52) | SIGMAR1GAAKDM4ELMNA | |
| SCHEMBL5577817 | 0.88 | SIGMAR1 (0.52) | SIGMAR1GAAKDM4ELMNA | |
| SCHEMBL5577702 | 0.88 | MCHR1 (0.51) | SIGMAR1GAAKDM4ELMNAALDH1A1 | |
| SCHEMBL5577520 | 0.87 | SIGMAR1 (0.45) | SIGMAR1GAAKDM4ELMNACACNA1G | |
| SCHEMBL5577870 | 0.87 | SIGMAR1 (0.47) | SIGMAR1UBE2MDCUN1D1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | SIGMAR1 3281/4885GAA 3806/4885KDM4E 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.